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A B S T R A C T
Prostaglandins (PGs) are lipid compounds that mediate the variety of physiological and pathological functions in al-
most all body tissues and organs. Prostacyclin (prostaglandin I2, PGI2), which is synthesized by the vascular endothe-
lium, is a potent vasodilator, inhibits the aggregation of platelets in vitro and has cytoprotective effect on gastrointestinal
mucosa. The aim of this study was to determine whether PGI2 is playing a role in host defense to toxic effect of aceta-
minophen (APAP). This was investigated in C57Black/6 mice which were intoxicated with single lethal or high sublethal
dose of APAP. APAP was administered to mice by gastric lavage and PGI2 agonists or antagonists were given intra-
peritoneally (i.p.) 30 minutes before or 2 hours after administration of APAP. The toxicity of APAP was determined by ob-
serving the survival of mice during 48 hours, by measuring the concentration of alanine-aminotransferase (ALT) in
plasma 20–24 hours after APAP administration, and by liver histology. Mice were given either pure PGI2 (PGI2 sodium
salt), its stable agonist (iloprost) or inhibitor of prostacyclin (IP)-receptor (CAY-10441). The results have shown that
PGI2 exibits a strong hepatoprotective effect when it was given to mice either before or after APAP (both increase of sur-
vival of mice and decrease of plasma ALT levels were statistical significant). Iloprost has not shown a similar effect and
CAY-10441 increased toxic effect of APAP if given 2 hours after its administration. Histopathological changes in liver
generally support these findings. These investigations support the view that PGI2 is involved in defense of organism to
noxious effects of xenobiotics on liver.
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Introduction
Acetaminophen (Paracetamol, N-acetyl-p-aminophe-
nol, APAP), the widely used antipyretic and analgesic
drug, is very safe at therapeutic doses1. However, over-
dose or chronic use of a high dose of APAP is major cause
of acute liver failure (ALF) in the western world2,3.
Therefore, intoxication of laboratory animals with high
dose of APAP has become most frequently used experi-
mental model for the study of mechanisms and preven-
tion of acute hepatotoxicity of xenobiotics. Acetamino-
phen is primarily metabolized in the liver by glucuro-
nidation and sulphation; however, a small proportion un-
dergoes cytochrome P450 (CYP450)-mediated bioactiva-
tion to reactive metabolite, N-acetyl-p-benzoquinone imi-
ne (NAPQI), which is rapidly quenched by glutathione
(GSH)4,5. After an overdose of APAP, elevated levels of
the toxic NAPQI metabolite are generated, which can ex-
tensively deplete hepatocellular GSH, covalently bind to
cellular macromolecules with sequent modification of its
function, and finally cause hepatocyte death. The precise
biochemical mechanism of cell necrosis is not fully un-
derstood. However, it is generally recognized that there
is simultaneous involvement of covalent binding, lipid
peroxidation and oxidative stress, each contributing to
hepatocellular damage6,7.
Prostaglandins (PGs) are lipid-derived autacoids gen-
erated by sequential metabolism of arachidonic acid by
the cyclooxygenase (COX) and prostaglandin synthase
enzymes, which are responsible for the production of the
five principal bioactive prostaglandins generated in vivo:
PGE2, PGF2a, PGD2, PGI2 (prostacyclin), and TXA2
(thromboxane)8. Prostaglandins are ubiquitously produ-
ced and act locally in an autocrine or juxtacrine manner
to elicit a diverse set of pharmacological effects modulat-
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ing many physiological systems. The disorders in prosta-
glandin synthesis or production have been implicated in
a broad array of diseases including cancer, inflammation,
cardiovascular disease, and hypertension9.
Prostacyclin (PGI2) is the primary prostaglandin pro-
duced by endothelial cells and plays an important role in
vascular homeostasis as a result of its potent vasodi-
latory and antithrombotic effects10. Thus, prostacyclin
functionally opposes the effects of TXA2 and has been
shown to specifically inhibit platelet activation and TXA2-
-induced vascular proliferation following vascular inju-
ry11. The vasodilatory actions of prostacyclin have en-
abled its clinical use for reducing pulmonary vascular re-
sistance in individuals suffering from primary pulmo-
nary hypertension12. There are also evdences that pro-
stacyclin has beneficial effect on liver injury induced by
various toxic agents and conditions, such are hypoxia in
perfused liver ex vivo13 and hepatic injury in vivo due to
galactosamine14 or carbon tetrachloride15. Moreover, stu-
dies on isolated rat hepatocytes16 or human leucocytes17
demonstrated a protection by prostacyclin against car-
bon tetrachloride induced necrosis. Prostacyclin, also,
shows cytoprotective effect on gastrointestinal mucosa18.
However, the effect of PGI2 and its analogs or antago-
nists on APAP-induced hepatoxicity has not been system-
atically studied.
These results prompted us to investigate the influence
of administration of PGI2, its stabile analogue (iloprost),
and inhibitior of IP-receptor (CAY-10441) on APAP-in-
duced liver injury in mice.
Materials and Methods
Animals
C57Black/6 mice were raised in an animal colony unit
at the Department of Physiology, School of Medicine,
Zagreb. Mice of both sexes aged 12–16 weeks and weigh-
ing 20–25 g were used in all experiments. The cages were
stored in rooms with a 12 h light period from 6 a.m. to 6
p.m., and the temperature and relative humidity in the
animal room were 21±2 °C and 50±5%, respectively. The
cages were sanitized twice weekly. All mice were given
free access to tap water and standard mouse chow diet
(Diete Standard, Milano, Italy).
Chemicals
Pure APAP substance was a kind gift from the Belupo
pharmaceutical company (Koprivnica, Croatia). Pheno-
barbitone-sodium was obtained from Kemika (Zagreb,
Croatia). Since the PGI2 is rapidly bioconversed to
PGF1a19 (t1/2=2–3 min), in certain experiments we used
besides the pure PGI2 (sodium salt) also its stable struc-
tural analog-iloprost. PGI2 sodium salt was dissolved (1
mg/mL) in Tris buffer (1M, pH=8.5) and after appropri-
ate dilution in 5% bicarbonate administered at a dose of
10 mg/kg of b.w. (body weight), i.p., 30 min before or 2 h
after APAP. Iloprost, was supplied as a solution in methyl
acetate. In order to change the solvent, we evaporated
the methyl acetate under gentle stream of nitrogen and
dissolved the remaining substance (1 mg/mL) in phos-
phate buffered saline (PBS, pH=7.2). Iloprost was ad-
ministered to animals (0.1 or 0.5 mg/kg of b.w., i.p.) 30
min before APAP. Antagonist of IP-receptor (CAY-10441)
was supplied as a crystalline solid. Since CAY-10441 is
sparingly soluble in aqueous buffers, it was first dissol-
ved in an organic solvent, dimethyl formamide (DMF, 25
mg/mL), then diluted in aqueous solution (PBS, pH=7.2),
and finally injected to animals 30 min before or 2h after
APAP (2.0 mg/kg of b.w., i.p.). All these compounds were
purchased from Cayman Chemical, USA. The doses of
drugs for application in vivo were chosen from scarce
data in literature or according to toxicity data in our pre-
liminary experiments, in which the effects of the drugs
on survival of mice and gross macroscopic changes of
liver and other visceral organs were observed.
Induction of hepatitis with APAP
The procedure of Guarner et al.20 was followed with
slight modifications21. To induce hepatic drug-metaboliz-
ing enzymes, mice were given phenobarbitone-sodium in
drinking water during 7 days (0.3 g/L). Thereafter, mice
were fasted overnight and APAP was given by a gastric
lavage in a volume of 0.4 to 0.5 mL. Before application,
APAP was dissolved in heated PBS to which 1–2 drops of
Tween 20 were added. Animals were allowed for food 4
hours later. In all experiments, a dose of 200–300 mg/kg
of APAP was administered, which in our previous experi-
ments induced 63–70% mortality in control mice. Experi-
mental and control groups of mice countered 12 animals
(for determining survival of animals) or 6–10 animals
(for determining ALT activity and liver histology). Con-
trol animals received appropriate vehicle.
Plasma ALT activity
Alanine aminotransferase (ALT) levels were measu-
red 20–24 h after APAP administration. Plasma samples
were obtained by a procedure in which haemolysis was
undetectable. Mice were given 250 U heparin i.p. 15 min
before bleeding. Blood was collected by puncture of the
medial eye angle with heparinized glass capillary tubes.
Plasma was stored at –70 °C for 24h before ALT determi-
nation. ALT concentrations were measured by standard
laboratory techniques21.
Liver histology
Mice were scarified under light ether anesthesia by
cervical dislocation 24 h after APAP administration. Li-
ver lobes of each animal (6 to 8 animals per group) were
fixed in 4% buffered paraformaldehyde, dehydrated in
increasing concentrations of ethanol, and embedded in
paraffin. Thereafter, sections of tissue were cut at 5 mm
on a rotary microtome, mounted on clean glass slides and
dried overnight at 37 °C. The sections were cleared, hy-
drated, and stained with haematoxylin and eosin. Micro-
scopically, the liver damage was classified as follow: de-
gree 0. – there was no damage; degree 1. – occasional
vacuolar and fat changes; degree 2. – occasional evidence
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of hepatocytic necrosis with minimal inflammatory reac-
tion; degree 3. – spotty necrosis of hepatocytes with in-
flammatory reaction widely distributed throughout the
liver; and degree 4. – severe diffuse hepatocellular necro-
sis with panlobular acute inflammatory cell infiltration
and complete lobular disarray.
Statistical analysis
Results are expressed as X±SEM. Parametric meth-
ods were used, including students t-test. Differences in
survival between groups of mice were compared by c2-
-test, using Yates’s correction of the test when indicated.
Results
The effects of PGI2, CAY-10441 and iloprost on
APAP-induced mortality
In three separate experiments, APAP was always
given in dose of 300 mg/kg of b.w. PGI2 (10 mg/kg of b.w.,
i.p.) and CAY-10441 (2.0 mg/kg of b.w., i.p.) were given ei-
ther 30 min before or 2h after APAP administration.
Iloprost was given to mice only 30 min before APAP in
two different doses: 0.1 mg/kg and 0.5 mg/kg of b.w., i.p.
Control mice were given vehicle at the same time points.
The survival of mice was followed for 48h, as we and others
observed that almost all control mice either die within
this period or fully recover thereafter. Administration of
either PGI2 30 min before or 2h after APAP significantly
improved the survival of animals (5/12 and 6/12 vs. con-
trols: 0/12, p<0.05 for both comparisons, Figure 1a).
CAY-10441 decreased the survival of animals when given
either 30 min before or 2h after APAP (7/12 and 4/12 vs.
8/12); however, the differences did not reach statistical
significance (p>0.05 for both comparisons, Figure 1b).
Iloprost shows slight hepatoprotection against APAP-in-
duced hepatotoxicity when given before APAP. In doses of
0.1 mg/kg and 0.5 mg/kg it increased survival of mice in
comparison to control mice (6/12 and 4/12 vs. 3/12), but
the differences were not statistical significant (p>0.05
for both comparisons, Figure 1c).
Mice had been treated as in previous experiment, ex-
cept that mice were given lower dose of APAP (200 mg/kg
of b.w.). Blood was collected 20–24 h after APAP adminis-
tration. Figure 2 shows mean ALT levels (±SEM) ob-
tained in 7 to 10 mice per group. As seen (Figure 2a), pre-
treatment of mice with PGI2 significantly reduced ALT
level (1624±528 U/L vs. 3791±825 U/L, p<0.05). If given
2 hours after APAP, PGI2 only slightly reduced ALT level
(3605±504 U/L vs. 3791±825 U/L in control group, p>0.05).
Figure 2b shows that CAY-10441 increased ALT concen-
tration either if given before or after APAP; however, the
elevation of ALT level was significant only if it has been
given to mice 2h after APAP (2006±476 U/L vs. 436±124
U/L, p<0.05). PGI2 stabile analog, iloprost, decreased,
but not significantly, plasma level of ALT if given in
lower dose (0.1 mg/kg) before APAP (Figure 2c, 1494±477
U/L vs. 2447±1326 U/L, p>0.05). However, when given in



































































Fig. 1. Influence of PGI2, CAY-10441 and iloprost on survival of


















































Fig. 2. Influence of PGI2, CAY-10441 and iloprost on plasma ALT
levels in mice with APAP induced hepatitis.
a higher dose (0.5 mg/kg), iloprost supremely raised the
level of ALT.
All livers from the APAP-treated mice showed well de-
scribed centrilobular necrosis, which in some cases was
also accompanied by congestion of the sinusoids with
blood. Macroscopically, the whole liver surface of APAP
treated animals had a mottled appearance – dark red
hemorrhagic-necrotic spots were regularly scattered on
the yellowish background. Microscopically, severity of
the necrosis was considerably variable, both between an-
imals and also within different parts of the same liver.
However, the necrosis appeared less marked in those
mice which had been treated with PGI2, and microscopic
damages of the liver parenchyma were more pronounced
in mice injected by CAY-10441 (Table 1).
Discussion
The presented results clearly show that PGI2 im-
proves the survival of mice before and after an APAP
overdose. Furthermore, hepatic damage, as assessed by
serum ALT concentration, was alleviated especially when
PGI2 was administered before APAP. Histopathological
findings, although not statistically significant, also point
at hepatoprotective effect of PGI2. These data are in
agreement with previous studies describing beneficial
protective effects of PGI2 and PGE2 against a variety of
hepatotoxins other than acetaminophen: ethanol, carbon
tetrachloride15, aflatoxin22, concanavalin A23, D-galacto-
samine14, LPS (endotoxin) alone, or associated with D-
-galactosamine24. In the present study the results differ
from data obtained by Guarner and colleagues20, which
obtained hepatoprotection only if PGI2 was given after
APAP. We gotened hepatoprotection with PGI2, both
when it was injected to mice before or after APAP. We
have not rational explanation for this difference, since
the dose of the drug and design of experiment was practi-
cally identical (besides mouse strains used, all other ex-
perimental conditions were practically identical in two
experiments).
There are insufficient data about in vivo action of
iloprost in a model of APAP-induced mortality in labora-
tory animals. Most data on protective effect of iloprost on
action of chemical toxicants are obtained in a model of
hepatocytes grown in vitro25–27. According to these find-
ings in vitro and data on hepatoprotective effect of PGI2,
we supposed that iloprost, a stabile analog of PGI2, will
show a strong hepatoprotective effect in our experi-
ments. However, neither 0.1 mg/kg nor 0.5 mg/kg ilo-
prost had any significant effect on the decrease of mor-
tality and serum ALT concentrations in mice treated
with APAP. The possible reason for that could be that
iloprost was injected to mice in a single and, perhaps, too
high dose. Bursch et colleagues have shown that iloprost
protects cultured rat hepatocytes in very narrow range of
doses (10–9–10–12 M) and in whole animal experiments it
was administered by continuous i.v. infusion (0.1 mg/kg/
min)25,27.
CAY-10441 is known as one of the most potent high-
-affinity ligands and functional antagonists for the hu-
man IP-receptor. In presented experiments it displayed
hepatodamaging action, as shown by significant increase
in mortality of animals, elevation in serum ALT level and
changes in liver morphology. To our best knowledge, this
is first time that CAY-10441 was used in vivo in a model
of experimental liver damage induced by toxic agent. The
mechanism of CAY-10441 hepatotoxic action is probably
due to the blockage of IP receptor, because the major of
its hepatotoxicity was expressed when it was given to
mice 2h after APAP administration. This indirectly sup-
ports the role of PGI2 as an endogenously produced
hepatoprotective agent. This is supported by our recent
preliminary observation that APAP alone increases syn-
thesis of PGI2 in the liver (]avar et al., unpublished ob-
servations). Nevertheless, we could not exclude its inter-
action with hepatic drug metabolism.
The origin of the prostanoids in APAP-induced liver
injury is not completely understood. APAP-induced hepa-
totoxicity was followed by significant elevation in pro-
stanoid biosynthesis (PGI2, PGE2 and TXA2) from liver
homogenates or fragments of treated animals20,21. He-
patocytes are PG-metabolizing rather than PG-synthe-
sizing cells that produce low amounts of prostanoids,
which probably act as autocrine modulators or partici-
pate in cell-to-cell communications between contiguous
hepatocytes28. Liver endothelial cells produce PGI2 as
the predominant metabolite, but also minor amounts of
PGE2 and TXA229. The major producers of prostanoids
are Kupffer cells and extrahepatic inflammatory cells re-
cruited to liver by chemoatractants30. Although the pre-
cise mechanisms underlying the cytoprotective effects of
PGs in acute liver injury remain to be precisely defined,
studies on isolated rat hepatocytes16 or human leuco-
cytes17 demonstrated a direct cellular protection by PGI2
against carbon tetrachloride induced necrosis, possibly
by stabilization of membranes or inhibition of lysosomal
enzyme release13,17,23. As a result of its potent vaso-
dilatory and antithrombotic effects (by inhibiting pla-
telet aggregation)14, PGI2 functionally opposes the ef-
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TABLE 1








a Dose of APAP was 200 mg/kg
b N=6–8 animals per group, PGI2 was given 30 min before and
CAY-10441 2 h after APAP
c Determined 20–24 h after APAP administration
d p>0.05
fects of TXA2 and thus may reduce or reverse the hepatic
vascular congestion observed in APAP toxicity. Guarner
et colleagues also have reported that thromboxane (TX)
blockade by itself does not protects against hepatic ne-
crosis induced by APAP, but the increased PGI2 produc-
tion after selective TX synthetase inhibition may play a
role in preventing liver damage20. However, our investi-
gations imply that PGI2 prevents hepatic damage also by
other mechanism, since it showed hepatoprotective ef-
fect also when applied before APAP administration. We
are presently investigating the possible mechanism of
protective effect of PGI2 and its derivatives on sub-
cellular and biochemical level.
Taken together with our previous investigations, these
findings support the view that PGI2 is, similarly to more
extensively studied PGE2, involved in defense of organ-
ism to noxious effects of xenobiotics on liver.
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ULOGA PROSTACIKLINA U MEHANIZMIMA AKUTNOG TOKSI^NOG O[TE]ENJA JETRE
ACETAMINOFENOM U MI[EVA
S A @ E T A K
Prostaglandini (PG) su spojevi koji nastaju razgradnjom lipida stani~ne membrane te posreduju u mnogim fizio-
lo{kim i patofiziolo{kim zbivanjima u gotovo svim organima i tkivima u organizmu. Prostaciklin (prostaglandin I2,
PGI2), kojeg stvara endotel krvnih `ila, je sna`an vazodilatator i inhibitor agregacije trombocita in vitro. PGI2 tako|er
{titi sluznicu probavnog sustava od toksi~nog djelovanja razli~itih agenasa (citoprotektivni u~inak). Cilj ovog istra-
`ivanja bio je ispitati ulogu PGI2 u obrani organizma od toksi~nog u~inka acetaminofena (APAP). Pokusi su bili obav-
ljeni na visokosrodnim mi{evima soja C57Black/6 kojima je gastri~nom sondom u{trcana letalna ili visoka subletalna
doza APAP. Agonisti (~isti PGI2-natrijeva sol ili stabilni analog PGI2-iloprost) i antagonist (CAY-10441) PGI2-receptora
u{trcani su intraperitonealno (i.p.) 30 minuta prije ili 2 sata nakon primjene APAP. Toksi~nost APAP odre|ivala se na
temelju 48-satnog pra}enja pre`ivljenja `ivotinja, mjerenja koncentracije alanin aminotransferaze (ALT) u plazmi 20–24
sata nakon aplikacije APAP i odre|ivanja histolo{kog stupnja o{te}enja jetre. Rezultati su pokazali da PGI2 ima sna`an
hepatoprotektivni u~inak (statisti~ki zna~ajno pove}anje pre`ivljenja `ivotinja i smanjenje razine ALT u plazmi u odno-
su na kontrolne skupine `ivotinja). Iloprost nije pokazao zna~ajan u~inak na toksi~nost APAP, a CAY-10441 je pove}ao
hepatotoksi~ni u~inak APAP kad je bio u{trcan 2 sata nakon njegove primjene. Patohistolo{ke promjene u jetri op}enito
potvr|uju prethodne rezultate. Ovo istra`ivanje potkrjepljuje tezu da je PGI2 jedan od endogenih posrednika u obrani
organizma od {tetnog djelovanja hepatotoksi~nih agenasa.
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